Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Brokerages

Key Points

• Analyst consensus: Five analysts give Eton an average rating of "Hold" (1 sell, 1 hold, 3 buy) with a 12‑month average target of $39.33.
• Recent research moves: Several brokers raised targets or ratings — Wall Street Zen upgraded to buy, Craig Hallum, B. Riley and HC Wainwright lifted targets (HC Wainwright to $52) while Weiss reaffirmed a sell.
• Company performance: Shares opened at $23.02 (52‑week range $13.09–$27.28) with a market cap of ~$628M; the latest quarter missed EPS ($0.05 vs. $0.12) despite slightly higher revenue, and the company reported negative net margin and ROE.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) has earned an average rating of "Hold" from the five analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $39.3333.

ETON has been the subject of a number of analyst reports. Wall Street Zen raised shares of Eton Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, March 21st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, March 20th. B. Riley Financial raised their target price on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a "buy" rating in a research note on Friday, March 20th. Finally, HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a "buy" rating in a research note on Friday, March 20th.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $23.02 on Monday. Eton Pharmaceuticals has a fifty-two week low of $13.09 and a fifty-two week high of $27.28. The company has a 50 day simple moving average of $21.42 and a two-hundred day simple moving average of $18.35. The company has a market capitalization of $627.99 million, a price-to-earnings ratio of -127.88 and a beta of 0.97. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.57.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.60%. The business had revenue of $21.28 million for the quarter, compared to the consensus estimate of $20.58 million. Analysts expect that Eton Pharmaceuticals will post 0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. grew its holdings in shares of Eton Pharmaceuticals by 0.3% during the second quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company's stock valued at $40,755,000 after buying an additional 7,930 shares during the last quarter. Vanguard Group Inc. grew its position in Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company's stock worth $29,208,000 after purchasing an additional 31,942 shares during the period. State Street Corp grew its position in Eton Pharmaceuticals by 14.5% in the 4th quarter. State Street Corp now owns 501,925 shares of the company's stock worth $8,488,000 after purchasing an additional 63,480 shares during the period. Cannell Capital LLC grew its position in Eton Pharmaceuticals by 17.3% in the 3rd quarter. Cannell Capital LLC now owns 455,405 shares of the company's stock worth $9,896,000 after purchasing an additional 67,230 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock worth $4,620,000 after acquiring an additional 217,042 shares during the last quarter. Hedge funds and other institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.